Actinium announced ATNM-400, a novel, non-PSMA targeting, first in class radiotherapy for prostate cancer utilizing the Actinium-225 ...

Actinium holds 230 patents and patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron. This press release may contain projections or other ...

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced it has entered into an agreement for the supply ...

EQS-News: Eckert & Ziegler SE / Key word (s): Agreement/Incoming Orders Eckert & Ziegler to Supply Actinium Pharmaceuticals with Ac-225 for Comprehensive Development Activities 25.03.2025 / 09:30 ...

While Novartis and Bayer got there first, AstraZeneca, Bristol Myers Squibb and Eli Lilly are all vying to bring their ...

Actinium Pharmaceuticals Inc. has unveiled ATNM-400, a novel non-PSMA-targeting, first-in-class radiotherapy for prostate cancer utilizing the Actinium-225 (Ac-225) radioisotope.

As anticipated, we have seen robust tumor control and ATNM-400 has shown to be well tolerated in preclinical studies, which we believe is due to the precise and potent cell-killing of Ac-225.

Actinium Pharmaceuticals will have access to Eckert & Ziegler's high-quality Actinium-225 to further develop its lead product Actimab-A as well as additional early and late-stage development ...

Title: ATNM-400 is a novel Actinium-225 antibody radioconjugate with strong efficacy in preclinical models of prostate cancer ...

Actinium Pharma inks supply agreement with Eckert & Ziegler for Ac-225 radioisotope to support comprehensive development activities: New York Wednesday, March 26, 2025, 18:00 Hrs ...

Inc. announced that they have entered into an agreement for the supply of Actinium-225 (Ac-225). With this agreement, Actinium Pharmaceuticals will have access to Eckert & Ziegler's high-purity ...

As anticipated, we have seen robust tumor control and ATNM-400 has shown to be well tolerated in preclinical studies, which we believe is due to the precise and potent cell-killing of Ac-225. We are ...